Thermo Fisher Scientific Accula System Promotional Offers

The promotional test kit will be sent directly to your company location from Thermo Fisher Scientific.

Offer available from January 1, 2023 - March 31, 2023

Redeem: Contact your Thermo Fisher Scientific Account Manager or call us at 858-401-8282 or email us at accula.promo@thermofisher.com

Terms and Conditions Apply*

Your promotional dock will be sent directly to your company location from Thermo Fisher Scientific.

Offer available from January 1, 2023 - March 31, 2023

Redeem: Contact your Thermo Fisher Scientific Account Manager or call us at 858-401-8282 or email us at accula.promo@thermofisher.com

Terms and Conditions Apply**

The Accula SARS-CoV-2 Test is for use under Emergency Use Authorization (EUA) Only. For Prescription Use Only. For In Vitro Diagnostic Use. © 2022 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified.

* Terms and Conditions: This promotion is open only to customers in the USA (excluding Puerto Rico) who purchase at least four (4) Accula SARS-CoV-2 or Flu A/Flu B test kits in a single purchase order. Offer valid for qualifying orders received by Thermo Fisher Scientific no later than March 31, 2023, or until promotional supplies are depleted, whichever comes first. Accula SARS-CoV-2 and Flu A/Flu B promotional kits are limited to three (3) redemptions per customer. Cannot be combined with other discounts or promotions. Offer void where prohibited, licensed or restricted by federal, state, provincial, or local laws or regulation or agency/institutional policy. Other restrictions may apply. Customer acknowledges that this offer may include a discount or other price reduction that must be properly and accurately accounted for and reported by customer in accordance with all federal and state laws, including without limitation the federal anti-kickback law (42 U.S.C. § 1320a-7b(b)(3)(A)) and regulations thereunder (42 C.F.R. §1001.952(h)).The Accula SARS-CoV-2 Test has not been FDA cleared or approved but has been authorized for emergency use by FDA for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. The test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.

** This promotion is open only to customers in the USA (excluding Puerto Rico) who purchase Accula SARS-CoV-2 or FluA/Flu B test kits in a single purchase order. Offer valid for qualifying orders received by Thermo Fisher Scientific no later than March 31, 2023, or until promotional supplies are depleted, whichever comes first. Limited to ten (10) free Accula Docks per customer. Cannot be combined with other discounts or promotions. Offer void where prohibited, licensed or restricted by federal, state, provincial, or local laws or regulation or agency/institutional policy. Other restrictions may apply. Customer acknowledges that this offer may include a discount or other price reduction that must be properly and accurately accounted for and reported by customer in accordance with all federal and state laws, including without limitation the federal anti-kickback law (42 U.S.C. § 1320a-7b(b)(3)(A)) and regulations thereunder (42 C.F.R. §1001.952(h)). The Accula SARS-CoV-2 Test has not been FDA cleared or approved but has been authorized for emergency use by FDA for use by laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) of 1988, 42 U.S.C. §263a, that meet requirements to perform high, moderate, or waived complexity tests. The test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation. This test has been authorized only for the detection of nucleic acid from SARS-CoV-2, not for any other viruses or pathogens. The emergency use of this test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.